WEBINAR: Phase 3 Study of ION582
April 23 at 1PM ESTLast November, Ionis Pharmaceuticals announced their phase 3 trial for ION582, called REVEAL, an investigational ASO for the potential treatment of Angelman syndrome.
The Phase 3 Efficacy and Safety Study of ION582 (ASO), is now listed on ClinicalTrials.gov.
ASF and FAST will host a webinar about the trial, named Reveal, with the Ionis team.
April 23, 2025 at 1:00 PM EST
